STOCK TITAN

MBX Biosciences (MBX) Stock Price, News & Analysis

MBX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
64 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+20.2% close of June 11, 2026
1-year change
+83.3% closing prices, November 20, 2025 to November 20, 2026
1-month change
-7.4% closing prices, October 20, 2026 to November 20, 2026

Company Description

MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. According to its SEC filings and investor communications, the company is advancing product candidates built on its proprietary Precision Endocrine Peptide™ (PEP™) platform, which is designed to address key limitations of traditional peptide therapies.

Business focus and PEP™ platform

MBX Biosciences describes its PEP™ platform as a proprietary approach to peptide drug design intended to improve clinical outcomes and simplify disease management for patients with endocrine and metabolic diseases. The company states that its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles, consistent drug concentrations with low peak-to-trough ratios, consistent exposure to target tissues, and less frequent dosing. This platform underpins multiple clinical and preclinical programs targeting conditions with significant unmet medical needs and established regulatory endpoints.

The company reports that it was founded by global leaders in peptide drug design and development and is incorporated in Delaware. MBX Biosciences is based in Carmel, Indiana, and its common stock is listed on the Nasdaq Global Select Market under the symbol MBX, as disclosed in its registration statement on Form S-1.

Key clinical programs

MBX Biosciences highlights three main clinical-stage programs built on its PEP™ platform:

  • Canvuparatide (MBX 2109) – chronic hypoparathyroidism (HP): Canvuparatide is described as a parathyroid hormone (PTH) peptide prodrug designed as a potential long-acting hormone replacement therapy for adults with chronic hypoparathyroidism. The company reports that canvuparatide is intended to provide continuous, infusion-like PTH exposure with convenient once-weekly administration. In a Phase 1 trial, canvuparatide demonstrated an extended half-life and a low peak-to-trough ratio, and was generally well tolerated, according to the S-1. MBX later announced positive topline results from the Phase 2 Avail™ trial, stating that the study achieved its primary composite endpoint at 12 weeks and showed responder rates at both 12 weeks and six months in an open-label extension. The company has indicated that canvuparatide is preparing for Phase 3 development for chronic hypoparathyroidism.
  • Imapextide (MBX 1416) – post-bariatric hypoglycemia (PBH): Imapextide is described as a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist designed as a potential once-weekly therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX reports that Phase 1 data showed dose-proportional exposure, a median half-life supportive of once-weekly dosing, and a favorable safety profile with no treatment-related serious adverse events. The company is evaluating imapextide in the Phase 2a STEADI™ trial in patients with PBH.
  • MBX 4291 and obesity portfolio – obesity: MBX 4291 is described as a glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic peptide (GIP) receptor co-agonist prodrug and a lead candidate in the company’s obesity portfolio. MBX states that MBX 4291 is a long-acting co-agonist with potential for once-monthly dosing and is being evaluated in a Phase 1 trial in adults with obesity, using single and multiple ascending dose designs. Company disclosures also refer to additional discovery and preclinical obesity candidates, including an amycretin prodrug and a GLP-1/GIP/glucagon receptor (GCGR) prodrug candidate, each designed for once-monthly dosing.

Therapeutic areas and disease focus

Across its pipeline, MBX Biosciences focuses on endocrine and metabolic disorders that it characterizes as having clinically validated targets, established endpoints for regulatory approval, and substantial unmet medical needs. The company’s communications emphasize:

  • Chronic hypoparathyroidism (HP): A rare endocrine disease caused by parathyroid hormone deficiency, leading to hypocalcemia and associated symptoms and complications. MBX notes that standard care often relies on high doses of oral calcium and active vitamin D supplements and does not address the underlying PTH deficiency. Canvuparatide is intended as a potential long-acting PTH replacement therapy for HP.
  • Post-bariatric hypoglycemia (PBH): A chronic complication following bariatric surgery characterized by hypoglycemic events. Imapextide is being studied as a potential therapy to reduce insulin secretion and increase blood glucose to reduce the frequency and severity of such events.
  • Obesity: Through MBX 4291 and additional obesity candidates, the company is developing precision peptide approaches targeting GLP-1, GIP, and GCGR pathways, with a focus on long-acting profiles and less frequent dosing.

Clinical-stage, emerging growth profile

MBX Biosciences identifies itself in its S-1 registration statement as a clinical-stage biopharmaceutical company, an emerging growth company, and a smaller reporting company under U.S. securities laws. Its revenue model is not detailed in the provided materials, and the company’s disclosures focus on research and development activities, clinical trial progress, and capital raising through public offerings.

The company has reported multiple public equity offerings, including an upsized underwritten offering of common stock, with net proceeds intended primarily to advance development of its three clinical-stage programs and to support discovery research, additional clinical development, and general corporate purposes.

Geographic base and listing

According to its SEC filings, MBX Biosciences is incorporated in Delaware and based in Carmel, Indiana. Its common stock trades on the Nasdaq Global Select Market under the ticker symbol MBX. The company participates in healthcare and investor conferences and uses webcasts and press releases to communicate clinical and corporate milestones.

Stock Performance

$49.55
-7.23%
-3.86
Last updated: at
+83.3%
Performance 1 year
49.7M
Shares outstanding As of November 5, 2026.

MBX Biosciences (MBX) closed at $49.55 on November 20, 2026. Over the past 12 months, the price has gained 83.3%.

See what a $1,000 investment in MBX would be worth today

Average down calculator for MBX

MBX Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

MBX Biosciences has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include earnings, conferences, management, clinical trial. View all MBX news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
5,266
Shares Sold
2
Transactions
Most Recent Transaction
Hoerter Steven L. (Chairman, President and CEO) sold 4,893 shares @ $54.82 on November 10, 2026

Insider selling at MBX Biosciences over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

MBX Biosciences reported operating income of -$98.1M in FY2025, and net income was -$87.0M. Diluted earnings per share stood at -$2.38. The company generated -$79.9M in operating cash flow. The current ratio was 24.62, measuring current assets divided by current liabilities.

-$87.0M
Net Income (FY2025)
-$79.9M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
30
December 30, 2026 Clinical

Week 26 primary analysis

Primary analysis at Week 26 after trial start; primary endpoint assessment, then open-label extension
YEAR
2027
2027 Clinical

Topline results

Topline results from MBX 4291 Phase 1 clinical trial
MAR
09
March 9, 2027 Corporate

25% option vesting

25% of 130,000 options vests for CBO; exercise price $32.29
MAR
09
March 9, 2027 - March 9, 2030 Corporate

Monthly option vesting

Remaining 75% vests monthly over three years starting Mar 9, 2027
APR
03
April 3, 2036 Corporate

Option expiration

10-year term ends for 130,000 options granted Apr 3, 2026

MBX Biosciences has 5 upcoming scheduled events. The next event, "Week 26 primary analysis", is scheduled for December 30, 2026 (in 38 days). Investors can track these dates to stay informed about potential catalysts that may affect the MBX stock price.

Short Interest History

Last 12 Months

Short interest in MBX Biosciences (MBX) currently stands at 4.3 million shares, down 3.1% from the previous reporting period, representing 11.1% of the float.

Days to Cover History

Last 12 Months

Days to cover for MBX Biosciences (MBX) currently stands at 7.9 days, up 5.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.9 to 11.4 days.

MBX Company Profile & Sector Positioning

MBX Biosciences (MBX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MBX often look at related companies in the same sector, including Celcuity Inc. (CELC), Pharvaris N.V. (PHVS), Xencor, Inc. (XNCR), Viking Therapeutics, Inc (VKTX), and Dyne Therapeutics, Inc. (DYN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MBX's relative position within its industry.

Frequently Asked Questions

The current stock price of MBX Biosciences (MBX) is $49.55 as of November 20, 2026.

The market cap of MBX Biosciences (MBX) is approximately $2.5B. Learn more about what market capitalization means .

The FY2025 net income of MBX Biosciences (MBX) is -$87.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of MBX Biosciences (MBX) is -$2.38 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of MBX Biosciences (MBX) is -$79.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of MBX Biosciences (MBX), current assets divided by current liabilities, was 24.62 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of MBX Biosciences (MBX) is -$98.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, based on its proprietary Precision Endocrine Peptide™ (PEP™) platform.

The company states that its PEP™ platform is designed to overcome key limitations of unmodified and modified peptide therapies by selectively engineering peptides with extended time-action profiles, consistent drug concentrations with low peak-to-trough ratios, consistent exposure to target tissues, and less frequent dosing.

MBX Biosciences targets endocrine and metabolic disorders. Its disclosed pipeline includes programs for chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity, all described as areas with significant unmet medical needs and established regulatory endpoints.

Canvuparatide (MBX 2109) is MBX Biosciences’ lead product candidate, described as a parathyroid hormone peptide prodrug designed as a potential long-acting hormone replacement therapy for chronic hypoparathyroidism. It is intended to provide continuous, infusion-like PTH exposure with convenient once-weekly administration and has completed a Phase 2 trial with positive topline results reported by the company.

Imapextide (MBX 1416) is described as a long-acting GLP-1 receptor antagonist being developed as a potential once-weekly therapy for post-bariatric hypoglycemia. MBX reports Phase 1 data supportive of once-weekly dosing and a favorable safety profile, and it is evaluating imapextide in a Phase 2a STEADI™ trial.

MBX 4291 is a glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic peptide (GIP) receptor co-agonist prodrug and the lead candidate in the company’s obesity portfolio. It is described as a long-acting agent with potential for once-monthly dosing and is being studied in a Phase 1 trial in adults with obesity.

According to its S-1 registration statement, MBX Biosciences, Inc. is incorporated in Delaware and based in Carmel, Indiana.

MBX Biosciences’ common stock is listed on the Nasdaq Global Select Market under the ticker symbol MBX, as disclosed in its SEC registration materials.

In its S-1 filing, MBX Biosciences identifies itself as an emerging growth company and a smaller reporting company, and it notes that it is a clinical-stage biopharmaceutical company.

The company’s SEC filings state that net proceeds from its public offerings are intended primarily to advance development of its three clinical-stage programs, fund discovery research and additional clinical development, and support general corporate purposes, working capital, and capital expenditures.